Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.

Ahrens-Nicklas RC, Clancy CE, Christini DJ.

Cardiovasc Res. 2009 Jun 1;82(3):439-47. doi: 10.1093/cvr/cvp083. Epub 2009 Mar 5.

2.
3.

Molecular biology of the long QT syndrome: impact on management.

Priori SG, Napolitano C, Paganini V, Cantù F, Schwartz PJ.

Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 2):2052-7. Review.

PMID:
9272507
4.

A molecular basis for the therapy of the long QT syndrome.

Priori SG, Napolitano C, Schwartz PJ.

Arch Mal Coeur Vaiss. 1996 Sep;89(9):1185-7.

PMID:
8952843
6.

Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.

Calvillo L, Spazzolini C, Vullo E, Insolia R, Crotti L, Schwartz PJ.

Heart Rhythm. 2014 Jan;11(1):126-32. doi: 10.1016/j.hrthm.2013.10.029. Epub 2013 Oct 14.

7.

Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.

Fabritz L, Damke D, Emmerich M, Kaufmann SG, Theis K, Blana A, Fortmüller L, Laakmann S, Hermann S, Aleynichenko E, Steinfurt J, Volkery D, Riemann B, Kirchhefer U, Franz MR, Breithardt G, Carmeliet E, Schäfers M, Maier SK, Carmeliet P, Kirchhof P.

Cardiovasc Res. 2010 Jul 1;87(1):60-72. doi: 10.1093/cvr/cvq029. Epub 2010 Jan 28.

8.
10.

Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.

Shimizu W, Antzelevitch C.

J Electrocardiol. 1999;32 Suppl:177-84. Review.

PMID:
10688323
11.

Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome.

Chinushi M, Izumi D, Iijima K, Ahara S, Komura S, Furushima H, Hosaka Y, Aizawa Y.

Europace. 2008 Feb;10(2):249-55. doi: 10.1093/europace/eun002.

PMID:
18256131
12.

Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.

Sicouri S, Antzelevitch D, Heilmann C, Antzelevitch C.

J Cardiovasc Electrophysiol. 1997 Nov;8(11):1280-90.

PMID:
9395171
14.

Efficacy of different beta-blockers in the treatment of long QT syndrome.

Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ.

J Am Coll Cardiol. 2014 Sep 30;64(13):1352-8. doi: 10.1016/j.jacc.2014.05.068.

15.

Influence of epinephrine, propranolol, and atrial pacing on spatial distribution of recovery time measured by body surface mapping in congenital long QT syndrome.

Shimizu W, Kamakura S, Kurita T, Suyama K, Aihara N, Shimomura K.

J Cardiovasc Electrophysiol. 1997 Oct;8(10):1102-14.

PMID:
9363813
16.

Management of asthma in children with long QT syndrome.

Collins S, Widger J, Davis A, Massie J.

Paediatr Respir Rev. 2012 Jun;13(2):100-5. doi: 10.1016/j.prrv.2011.02.003. Epub 2011 Mar 10. Review.

PMID:
22475256
17.

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome.

Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T, Shimomura K.

J Am Coll Cardiol. 1995 Nov 1;26(5):1299-309.

18.

Role of alpha1-blockade in congenital long QT syndrome: investigation by exercise stress test.

Furushima H, Chinushi M, Washizuka T, Aizawa Y.

Jpn Circ J. 2001 Jul;65(7):654-8.

19.

Congenital long QT syndromes: prevalence, pathophysiology and management.

Barsheshet A, Dotsenko O, Goldenberg I.

Paediatr Drugs. 2014 Dec;16(6):447-56. doi: 10.1007/s40272-014-0090-4. Review.

PMID:
25288402
20.

Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome.

Antzelevitch C, Yan GX, Shimizu W.

J Electrocardiol. 1999;32 Suppl:158-65. Review.

PMID:
10688320

Supplemental Content

Support Center